Carl D Richards Selected Research

Oncostatin M

1/2020	IL-33 Mediates Lung Inflammation by the IL-6-Type Cytokine Oncostatin M.
1/2020	RELMα is Induced in Airway Epithelial Cells by Oncostatin M Without Requirement of STAT6 or IL-6 in Mouse Lungs In Vivo.
12/2019	Oncostatin M in the Regulation of Connective Tissue Cells and Macrophages in Pulmonary Disease.
1/2019	Extracellular Matrix and Fibrocyte Accumulation in BALB/c Mouse Lung upon Transient Overexpression of Oncostatin M.
1/2018	Separate roles of IL-6 and oncostatin M in mouse macrophage polarization in vitro and in vivo.
1/2016	Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation.
9/2014	Oncostatin M overexpression induces matrix deposition, STAT3 activation, and SMAD1 Dysregulation in lungs of fibrosis-resistant BALB/c mice.
12/2013	The enigmatic cytokine oncostatin m and roles in disease.
8/2013	Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation.
1/2013	Oncostatin M and TLR-4 ligand synergize to induce MCP-1, IL-6, and VEGF in human aortic adventitial fibroblasts and smooth muscle cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carl D Richards Research Topics

Disease

13	Inflammation (Inflammations) 01/2020 - 05/2002
7	Lung Diseases (Lung Disease) 01/2020 - 01/2011
6	Neoplasms (Cancer) 01/2018 - 09/2008
4	Infections 01/2022 - 04/2012
3	Fibrosis (Cirrhosis) 10/2017 - 09/2012
3	Atherosclerosis 01/2016 - 01/2013
3	Arthritis (Polyarthritis) 01/2005 - 05/2002
2	Communicable Diseases (Infectious Diseases) 01/2022 - 05/2012
2	Asthma (Bronchial Asthma) 01/2021 - 04/2006
2	Eosinophilia 01/2021 - 01/2011
2	Pneumonia (Pneumonitis) 01/2020 - 08/2013
2	Melanoma (Melanoma, Malignant) 01/2018 - 05/2012
2	Rheumatoid Arthritis 12/2013 - 06/2003
2	Osteitis 04/2012 - 06/2003
2	Osteosarcoma (Osteogenic Sarcoma) 04/2011 - 09/2008
2	Respiratory Hypersensitivity 01/2011 - 09/2005
2	Necrosis 09/2008 - 01/2005
1	Human Influenza (Influenza) 01/2022
1	Virus Diseases (Viral Diseases) 01/2022
1	Hypothermia 01/2022
1	Viral Pneumonia 01/2022
1	COVID-19 01/2022
1	Bronchiectasis 01/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Bronchitis 01/2021
1	Job Syndrome (Hyper-IgE Syndrome) 01/2021
1	Reinfection 01/2021
1	Hepatitis C 12/2019
1	Experimental Melanoma 01/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2016
1	Body Weight (Weight, Body) 01/2014
1	Overweight 01/2014
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2013
1	Idiopathic Pulmonary Fibrosis 09/2012
1	Neoplasm Metastasis (Metastasis) 05/2012
1	Bone Resorption 04/2012
1	Chondrosarcoma 04/2011
1	Sarcoma (Soft Tissue Sarcoma) 04/2011
1	Pulmonary Eosinophilia (Eosinophilic Pneumonia) 01/2011
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2011
1	Hyperplasia 01/2011
1	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 06/2003
1	Joint Diseases (Joint Disease) 06/2003
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 04/2003

Drug/Important Bio-Agent (IBA)

19	Oncostatin MIBA 01/2020 - 05/2002
17	CytokinesIBA 01/2022 - 05/2002
10	Interleukin-6 (Interleukin 6)IBA 01/2022 - 05/2002
4	Interleukin-1 (Interleukin 1)IBA 01/2020 - 06/2003
3	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2015
3	Interleukin-33IBA 01/2020 - 10/2015
3	Interleukin-15 (Interleukin 15)IBA 12/2019 - 05/2012
2	Immunoglobulin E (IgE)IBA 01/2021 - 09/2005
2	Bleomycin (Blenoxane)FDA LinkGeneric 10/2017 - 09/2012
2	Interleukin-12 (IL 12)IBA 01/2017 - 05/2002
2	Transforming Growth Factors (Transforming Growth Factor)IBA 09/2014 - 09/2012
2	LigandsIBA 01/2013 - 04/2012
2	CollagenIBA 09/2012 - 01/2011
1	Interferon Type IIBA 01/2022
1	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 01/2022
1	SmokeIBA 01/2022
1	Matrix Metalloproteinases (MMPs)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Biological ProductsIBA 01/2021
1	Interleukin-5 (Interleukin 5)IBA 01/2021
1	Prednisone (Sone)FDA LinkGeneric 01/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021
1	benralizumabIBA 01/2021
1	ResistinIBA 01/2020
1	N-(3-pyridylmethyl)adriamycin (YM 1)IBA 01/2020
1	Antiviral Agents (Antivirals)IBA 12/2019
1	VaccinesIBA 12/2019
1	ChemokinesIBA 01/2019
1	Interleukin-13IBA 01/2019
1	AntigensIBA 01/2017
1	Apolipoproteins E (ApoE)IBA 01/2016
1	Bromodeoxyuridine (BrdU)IBA 01/2016
1	Imiquimod (Aldara)FDA LinkGeneric 01/2016
1	AntibodiesIBA 01/2016
1	Messenger RNA (mRNA)IBA 10/2015
1	Chemotactic FactorsIBA 02/2015
1	LipidsIBA 01/2014
1	InterleukinsIBA 09/2012
1	Cytokine Receptor gp130IBA 09/2012
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 04/2012
1	Cytostatic AgentsIBA 04/2011
1	StaurosporineIBA 09/2008
1	Phosphotransferases (Kinase)IBA 09/2008
1	midostaurinIBA 09/2008
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2006
1	Immunoglobulin G (IgG)IBA 09/2005
1	Proteoglycans (Proteoglycan)IBA 06/2003
1	ImmunosorbentsIBA 06/2003
1	EnzymesIBA 06/2003
1	peptide VDIPENIBA 06/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2003

Therapy/Procedure

5	Therapeutics 01/2022 - 04/2003
1	Immunotherapy 01/2017
1	Intradermal Injections 01/2016
1	Radiotherapy 04/2011
1	Drug Therapy (Chemotherapy) 04/2011